Loss of CDKN1B/p27Kip1 expression is associated with ERG fusion-negative prostate cancer, but is unrelated to patient prognosis

Oncology Letters

Volumn 6, Issue 5, 2013, Pages 1245-1252

  Sirma, Hüseyin ^a   Broemel, Margarethe ^a   Stumm, Laura ^a   Tsourlakis, Tina ^a   Steurer, Stefan ^a   Tennstedt, Pierre ^a   Salomon, Georg ^a   Michl, Uwe ^a   Haese, Alexander ^a   Simon, Ronald ^a   Sauter, Guido ^a   Schlomm, Thorsten ^a   Minner, Sarah ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

ERG fusion; p27; Prostate cancer

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CELL PROLIFERATION; DISEASE ASSOCIATION; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PROSTATE CANCER; PROTEIN EXPRESSION; TISSUE MICROARRAY;

EID: 84884475135     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1563     Document Type: Article

References (39)

1. Cooperberg MR, Cowan J, Broering JM, Carroll PR: High-risk prostate cancer in the United States, 1990-2007. World J Urol26: 211-218, 2008.
2. Samaratunga H and Epstein JI: What is the molecular pathology of low-risk prostate cancer? World J Urol26: 431-436, 2008.
3. Rubin MA, Maher CA and Chinnaiyan AM: Common gene rearrangements in prostate cancer. J Clin Oncol29: 3659-3668, 2011.
4. Tsihlias J, Kapusta L and Slingerland J: The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Annu Rev Med50: 401-423, 1999.
5. Wander SA, Zhao D and Slingerland JM: p27: a barometer of signaling deregulation and potential predictor of response to targeted therapies. Clin Cancer Res17: 12-18, 2011.
6. Swanson GP and Quinn D: Using molecular markers to help predict who will fail after radical prostatectomy. Prostate Cancer2011: 290160, 2011.
7. Tsihlias J, Kapusta LR, DeBoer G, etal: Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res58: 542-548, 1998.
8. Vis AN, Noordzij MA, Fitoz K, Wildhagen MF, Schröder FH and van der Kwast TH: Prognostic value of cell cycle proteins p27(kip1) and MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancer. J Urol164: 2156-2161, 2000.
9. Vis AN, van Rhijn BW, Noordzij MA, Schröder FH and vanderKwastTH: Value of tissue markers p27(kip1), MIB-1, and CD44s for the pre-operative prediction of tumour features in screen-detected prostate cancer. J Pathol197: 148-154, 2002.
10. Yang RM, Naitoh J, Murphy M, etal: Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol159: 941-945, 1998.
11. Revelos K, Petraki C, Gregorakis A, etal: p27(kip1) and Ki-67 (MIB1) immunohistochemical expression in radical prostatectomy specimens of patients with clinically localized prostate cancer. InVivo 19: 911-920, 2005.
12. Guo Y, Sklar GN, Borkowski A and Kyprianou N: Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade. Clin Cancer Res3: 2269-2274, 1997.
13. Kuczyk M, Machtens S, Hradil K, etal: Predictive value of decreased p27Kip1 protein expression for the recurrence-free and long-term survival of prostate cancer patients. Br J Cancer81: 1052-1058, 1999.
14. Kuczyk MA, Bokemeyer C, Hartmann J, etal: Predictive value of altered p27Kip1 and p21WAF/Cip1 protein expression for the clinical prognosis of patients with localized prostate cancer. Oncol Rep8: 1401-1407, 2001.
15. Cordon-Cardo C, Koff A, Drobnjak M, etal: Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J Natl Cancer Inst90: 1284-1291, 1998.
16. Cote RJ, Shi Y, Groshen S, etal: Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. J Natl Cancer Inst90: 916-920, 1998.
17. Cheville JC, Lloyd RV, Sebo TJ, etal: Expression of p27kip1 in prostatic adenocarcinoma. Mod Pathol11: 324-328, 1998.
18. Erdamar S, Yang G, Harper JW, etal: Levels of expression of p27KIP1 protein in human prostate and prostate cancer: an immunohistochemical analysis. Mod Pathol12: 751-755, 1999.
19. Halvorsen OJ, Haukaas SA and Akslen LA: Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. Clin Cancer Res9: 1474-1479, 2003.
20. Nassif AE and Tambara Filho R: Immunohistochemistry expression of tumor markers CD34 and P27 as a prognostic factor of clinically localized prostate adenocarcinoma after radical prostatectomy. Rev Col Bras Cir37: 338-344, 2010.
21. Vlachostergios PJ, Karasavvidou F, Kakkas G, etal: Lack of prognostic significance of p16 and p27 after radical prostatectomy in hormone-naïve prostate cancer. J Negat Results Biomed11: 2, 2012.
22. Wu TT, Wang JS, Jiaan BP, etal: Role of p21(WAF1) and p27(KIP1) in predicting biochemical recurrence for organ-confined prostate adenocarcinoma. J Chin Med Assoc70: 11-15, 2007.
23. Minner S, Enodien M, Sirma H, etal: ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res17: 5878-5888, 2011.
24. Minner S, Jessen B, Stiedenroth L, etal: Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer. Clin Cancer Res16: 1553-1560, 2010.
25. Thomas GV, Schrage MI, Rosenfelt L, etal: Preoperative prostate needle biopsy p27 correlates with subsequent radical prostatectomy p27, Gleason grade and pathological stage. JUrol164: 1987-1991, 2000.
26. Mukai M, Dong Q, Hardy MP, Kiyokawa H, Peterson RE and Cooke PS: Altered prostatic epithelial proliferation and apoptosis, prostatic development, and serum testosterone in mice lacking cyclin-dependent kinase inhibitors. Biol Reprod73: 951-958, 2005.
27. Shen MM and Abate-Shen C: Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev24: 1967-2000, 2010.
28. Sreenath TL, Dobi A, Petrovics G and Srivastava S: Oncogenic activation of ERG: A predominant mechanism in prostate cancer. J Carcinog10: 37, 2011.
29. Clark JP and Cooper CS: ETS gene fusions in prostate cancer. Nat Rev Urol6: 429-439, 2009.
30. Setlur SR, Mertz KD, Hoshida Y, etal: Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst100: 815-825, 2008.
31. Jhavar S, Brewer D, Edwards S, etal: Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer. BJU Int103: 1256-1269, 2009.
32. Brase JC, Johannes M, Mannsperger H, etal: TMPRSS2-ERG-specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling. BMC Cancer11: 507, 2011.
33. Taylor BS, Schultz N, Hieronymus H, etal: Integrative genomic profiling of human prostate cancer. Cancer Cell18: 11-22, 2010.
34. Müller J, Ehlers A, Burkhardt L, etal: Loss of p(Ser2448)-mTOR expression is linked to adverse prognosis and tumor progression in ERG-fusion-positive cancers. Int J Cancer 132, 1333-1340, 2012.
35. Minner S, Wittmer C, Graefen M, etal: High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. Prostate71: 281-288, 2011.
36. Tennstedt P, Köster P, Bruchmann A, etal: The impact of the number of cores on tissue microarray studies investigating prostate cancer biomarkers. Int J Oncol40: 261-268, 2012.
37. El Gammal AT, Bruchmann M, Zustin J, etal: Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer. Clin Cancer Res16: 56-64, 2010.
38. Schlomm T, Iwers L, Kirstein P, etal: Clinical significance of p53 alterations in surgically treated prostate cancers. Mod Pathol21, 1371-1378, 2008.
39. Schlomm T, Kirstein P, Iwers L, etal: Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer. Clin Cancer Res13: 6579-6584, 2007.